A Phase 2/3 interventional study of PF-06651600 Induction Dose and PF-06651600 Maintenance Dose #1 in Alopecia Areata, sponsored by Pfizer. Completed at 155 sites in 18 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-02-24.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.
Among the 17 studies in Alopecia Areata by Pfizer, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is the only one in phase 2/3, and was the 2nd registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Pfizer · Sites in United States, China, Czechia and 6 more countries
Ages 6–14
Pfizer · Sites in Korea, Republic of
Ages 12+
Pfizer · Sites in United States, Canada, China and 8 more countries
Ages 12+
By country, each count listing its studies:
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6
First in 2016; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 718 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 175 across the 10 interventional studies, 375 across the 6 observational. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Alopecia Areata by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Alopecia Areata by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
Drug: PF-06651600 Induction Dose · Drug: PF-06651600 Maintenance Dose #1
Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
Drug: PF-06651600 Induction Dose · Drug: PF-06651600 Maintenance Dose #2
Maintenance dose #1 given QD for 48 weeks
Drug: PF-06651600 Maintenance Dose #1
Maintenance dose #2 given QD for 48 weeks
Drug: PF-06651600 Maintenance Dose #2
Maintenance dose #3 given QD for 48 weeks
Drug: PF-06651600 Maintenance Dose #3
Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
Drug: PF-06651600 Induction Dose · Drug: PF-06651600 Maintenance Dose #1 · Drug: Placebo
Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
Drug: PF-06651600 Maintenance Dose #1 · Drug: Placebo
Oral tablets taken once daily (QD)
Oral tablets taken QD
Oral tablets taken QD
Oral tablets taken QD
Oral tablets taken QD
Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.
Time frame: Week 24
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
Time frame: Week 24
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
Time frame: Week 24
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24
PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
Time frame: Week 24
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model
The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Time frame: Week 24
Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model
The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Time frame: Week 24
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 20 at Week 4, 8, 12, 18, 28, 34, 40, and 48
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
Time frame: Week 4, 8, 12, 18, 28, 34, 40, and 48
Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 4, 8, 12, 18, 28, 34, 40, and 48
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<=10 were reported.
Time frame: Week 4, 8, 12, 18, 28, 34, 40, and 48
Percentage of Participants With at Least 75% Improvement in SALT Score (SALT75) From Baseline at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.
Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Change From Baseline in SALT Score at Week 4, 8, 12, 18, and 24
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 4, 8, 12, 18, and 24
Change From Baseline in SALT Score at Week 28, 34, 40, and 48
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 28, 34, 40, and 48
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyebrow Assessment (EBA) Score (Among Participants Without Normal EBA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.
Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Percentage of Participants With at Least a 2 Grade Improvement From Baseline or a Score of 3 in Eyelash Assessment (ELA) Score (Among Participants Without Normal ELA at Baseline) at Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.
Time frame: Week 4, 8, 12, 18, 24, 28, 34, 40, and 48
Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 4, 8, 12, 18, 24, 34, 40, and 48
PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
Time frame: Week 4, 8, 12, 18, 24, 34, 40, and 48
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 4, 8, 12, 18, and 24: Emotional Symptoms and Activity Limitations
AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 4, 8, 12, 18, and 24
Change From Baseline in Alopecia Areata Patient Priority Outcomes (AAPPO) Domain Scores at Week 34, 40, and 48: Emotional Symptoms and Activity Limitations
AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 34, 40, and 48
Percentage of Participants With Improvement From Baseline on Alopecia Areata Patient Priority Outcomes (AAPPO) Items 1-4 at Week 4, 8, 12, 18, 24, 34, 40, and 48
AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.
Time frame: Week 4, 8, 12, 18, 24, 34, 40, and 48
Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 4, 8, 12, and 24
Change From Baseline in Depression Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 48
Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Weeks 4, 8, 12, and 24
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 4, 8, 12, and 24
Change From Baseline in Anxiety Subscale Score of Hospital Anxiety and Depression Scale (HADS) at Week 48
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.
Time frame: Baseline (Day 1), Week 48
Percentage of Participants With a Baseline Score Indicative of Depression Achieving Normal Depression Subscale Score of HADS at Week 4, 8, 12, 24, and 48
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms.
Time frame: Week 4, 8, 12, 24 and 48
Percentage of Participants With a Baseline Score Indicative of Anxiety Achieving Normal Anxiety Subscale Score of HADS at Week 4, 8, 12, 24, and 48
HADS is a validated 14-item PRO measure used to assessed states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms.
Time frame: Week 4, 8, 12, 24 and 48
| Milestone | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Started | 132 | 130 | 130 | 132 | 63 | 65 | 66 |
| Completed | 122 | 124 | 121 | 117 | 58 | 63 | 61 |
| Not completed | 10 | 6 | 9 | 15 | 5 | 2 | 5 |
| Withdrew: Adverse event | 3 | 0 | 2 | 4 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 2 | 5 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 | 4 | 4 | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Started | 113 | 111 | 108 | 106 | 49 | 59 | 57 |
| Completed | 107 | 100 | 103 | 97 | 44 | 56 | 53 |
| Not completed | 6 | 11 | 5 | 9 | 5 | 3 | 4 |
| Withdrew: Adverse event | 0 | 2 | 2 | 1 | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 | 3 | 3 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 1 | 1 | 2 | 0 |
| Withdrew: Non-compliant with study drug | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Other | 1 | 4 | 0 | 2 | 0 | 0 | 0 |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score less than or equal to (\<=) 20 at week 24 were reported.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 | 30.65 (22.53 to 38.76) | 22.31 (14.90 to 29.73) | 23.39 (15.94 to 30.84) | 14.29 (8.00 to 20.57) | 1.69 (0.00 to 4.99) | 1.54 (0.00 to 3.65) |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 4 | 21.29 | 12.87 | 13.42 | 10.62 | 1.65 | 1.54 |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<= 10 at week 24 were reported.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants With an Absolute SALT Score of Less Than or Equal to 10 at Week 24: Analysis 1 | 21.77 (14.51 to 29.04) | 13.22 (7.19 to 19.26) | 13.71 (7.66 to 19.76) | 10.92 (5.32 to 16.53) | 1.69 (0.00 to 4.99) | 1.54 (0.00 to 3.65) |
PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants With Patient Global Impression of Change (PGI-C) Score of Moderately Improved or Greatly Improved at Week 24 | 52.19 | 45.40 | 49.17 | 41.95 | 11.36 | 9.23 |
The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=20 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=20 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 20 at Week 24: Maximum Effect (Emax) Model | 32.37 | 20.57 | 22.52 | 13.58 | 4.81 | 1.63 |
The exposure response of Ritlecitinib (PF-06651600) on the regrowth of scalp hair was characterized using a Bayesian three-parameter hyperbolic Emax model for the SALT score \<=10 at Week 24 with an additional term for effect of loading dose. In Emax exposure-response model the response function was the log odds of the percentage of participants with response based on SALT \<=10 at Week 24, which was fit on the logistic scale and then back-transformed to percentage. The effect of loading dose is included as fixed factor in the model. The variable that represents loading dose has values of 1 for groups 200/50 mg once daily and 200/30 mg once daily and of 0 for the remaining groups. SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Exposure Response of PF-06651600 on Regrowth of Lost Hair Based on Absolute SALT Score of Less Than or Equal to 10 at Week 24: Maximum Effect (Emax) Model | 21.29 | 13.76 | 14.43 | 9.02 | 3.88 | 1.66 |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 0.78 (0.00 to 2.29) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) |
| Week 8 | 5.47 (1.53 to 9.41) | 4.13 (0.59 to 7.68) | 2.46 (0.00 to 5.21) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) |
| Week 12 | 11.90 (6.25 to 17.56) | 8.87 (3.87 to 13.88) | 6.35 (2.09 to 10.61) | 3.28 (0.12 to 6.44) | 3.39 (0.00 to 8.01) | 1.64 (0.00 to 4.83) | 1.59 (0.00 to 4.67) |
| Week 18 | 19.83 (12.73 to 26.94) | 13.22 (7.19 to 19.26) | 13.11 (7.12 to 19.10) | 9.40 (4.11 to 14.69) | 3.33 (0.00 to 7.88) | 1.67 (0.00 to 4.91) | 1.61 (0.00 to 4.75) |
| Week 28 | 34.17 (25.68 to 42.65) | 23.53 (15.91 to 31.15) | 26.05 (18.16 to 33.94) | 20.49 (13.33 to 27.65) | 5.00 (0.00 to 10.51) | 1.75 (0.00 to 5.16) | 6.35 (0.33 to 12.37) |
| Week 34 | 38.40 (29.87 to 46.93) | 27.64 (19.74 to 35.55) | 33.87 (25.54 to 42.20) | 28.69 (20.66 to 36.71) | 5.08 (0.00 to 10.69) | 19.67 (9.70 to 29.65) | 9.23 (2.19 to 16.27) |
| Week 40 | 39.06 (30.61 to 47.51) | 33.33 (25.00 to 41.66) | 39.34 (30.68 to 48.01) | 30.00 (21.80 to 38.20) | 6.78 (0.36 to 13.19) | 23.08 (12.83 to 33.32) | 15.38 (6.61 to 24.16) |
| Week 48 | 39.53 (31.10 to 47.97) | 34.43 (26.00 to 42.86) | 43.20 (34.52 to 51.88) | 31.15 (22.93 to 39.37) | 9.84 (2.36 to 17.31) | 33.85 (22.34 to 45.35) | 18.75 (9.19 to 28.31) |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. In this outcome measure, percentage of participants with SALT score \<=10 were reported.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 0.78 (0.00 to 2.29) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) |
| Week 8 | 2.34 (0.00 to 4.96) | 0.83 (0.00 to 2.44) | 0.82 (0.00 to 2.42) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) |
| Week 12 | 6.35 (2.09 to 10.61) | 5.65 (1.58 to 9.71) | 5.56 (1.56 to 9.56) | 0.82 (0.00 to 2.42) | 1.69 (0.00 to 4.99) | 0.00 (NA to NA) | 1.59 (0.00 to 4.67) |
| Week 18 | 12.40 (6.52 to 18.27) | 7.44 (2.76 to 12.11) | 6.56 (2.16 to 10.95) | 5.13 (1.13 to 9.12) | 1.67 (0.00 to 4.91) | 1.67 (0.00 to 4.91) | 1.61 (0.00 to 4.75) |
| Week 28 | 29.17 (21.03 to 37.30) | 16.81 (10.09 to 23.53) | 18.49 (11.51 to 25.46) | 16.39 (9.82 to 22.96) | 3.33 (0.00 to 7.88) | 1.75 (0.00 to 5.16) | 3.17 (0.00 to 7.50) |
| Week 34 | 30.40 (22.34 to 38.46) | 18.70 (11.81 to 25.59) | 23.39 (15.94 to 30.84) | 22.13 (14.76 to 29.50) | 3.39 (0.00 to 8.01) | 13.11 (4.64 to 21.59) | 4.62 (0.00 to 9.72) |
| Week 40 | 31.25 (23.22 to 39.28) | 25.20 (17.53 to 32.88) | 27.05 (19.17 to 34.93) | 25.00 (17.25 to 32.75) | 3.39 (0.00 to 8.01) | 18.46 (9.03 to 27.89) | 9.23 (2.19 to 16.27) |
| Week 48 | 33.33 (25.20 to 41.47) | 27.87 (19.91 to 35.82) | 31.20 (23.08 to 39.32) | 25.41 (17.68 to 33.14) | 6.56 (0.35 to 12.77) | 24.62 (14.14 to 35.09) | 14.06 (5.55 to 22.58) |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. A SALT 75 response was a 75% or greater reduction from baseline in SALT score.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 0.78 (0.00 to 2.29) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) | 0.00 (NA to NA) |
| Week 8 | 4.69 (1.03 to 8.35) | 3.31 (0.12 to 6.49) | 1.64 (0.00 to 3.89) | 0.83 (0.00 to 2.44) | 0.00 (NA to NA) | 1.59 (0.00 to 4.67) | 0.00 (NA to NA) |
| Week 12 | 11.90 (6.25 to 17.56) | 8.06 (3.27 to 12.86) | 6.35 (2.09 to 10.61) | 2.46 (0.00 to 5.21) | 1.69 (0.00 to 4.99) | 1.64 (0.00 to 4.83) | 1.59 (0.00 to 4.67) |
| Week 18 | 20.66 (13.45 to 27.88) | 14.88 (8.54 to 21.22) | 9.84 (4.55 to 15.12) | 11.11 (5.42 to 16.81) | 1.67 (0.00 to 4.91) | 1.67 (0.00 to 4.91) | 1.61 (0.00 to 4.75) |
| Week 24 | 31.45 (23.28 to 39.62) | 20.66 (13.45 to 27.88) | 22.58 (15.22 to 29.94) | 13.45 (7.32 to 19.57) | 1.69 (0.00 to 4.99) | 1.54 (0.00 to 4.53) | 3.08 (0.00 to 7.28) |
| Week 28 | 34.17 (25.68 to 42.65) | 24.37 (16.66 to 32.08) | 27.73 (19.69 to 35.77) | 21.31 (14.04 to 28.58) | 5.00 (0.00 to 10.51) | 3.51 (0.00 to 8.29) | 4.76 (0.00 to 10.02) |
| Week 34 | 38.40 (29.87 to 46.93) | 32.52 (24.24 to 40.80) | 38.71 (30.14 to 47.28) | 28.69 (20.66 to 36.71) | 5.08 (0.00 to 10.69) | 21.31 (11.03 to 31.59) | 10.77 (3.23 to 18.31) |
| Week 40 | 39.84 (31.36 to 48.33) | 34.96 (26.53 to 43.39) | 42.62 (33.85 to 51.40) | 30.00 (21.80 to 38.20) | 5.08 (0.00 to 10.69) | 23.08 (12.83 to 33.32) | 15.38 (6.61 to 24.16) |
| Week 48 | 39.53 (31.10 to 47.97) | 36.07 (27.54 to 44.59) | 46.40 (37.66 to 55.14) | 31.15 (22.93 to 39.37) | 9.84 (2.36 to 17.31) | 32.31 (20.94 to 43.68) | 21.88 (11.75 to 32.00) |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Change at Week 4 | -2.3 (-3.64 to -1.01) | -2.7 (-4.03 to -1.35) | -1.8 (-3.16 to -0.50) | -1.3 (-2.60 to 0.06) | -1.3 (-3.19 to 0.69) | -0.9 (-2.17 to 0.46) |
| Change at Week 8 | -12.8 (-15.56 to -10.05) | -12.5 (-15.28 to -9.71) | -6.3 (-9.10 to -3.50) | -5.0 (-7.82 to -2.21) | -1.7 (-5.74 to 2.34) | -1.2 (-3.99 to 1.50) |
| Change at Week 12 | -22.7 (-26.47 to -18.97) | -20.1 (-23.87 to -16.30) | -12.4 (-16.18 to -8.61) | -10.3 (-14.11 to -6.47) | -3.5 (-9.00 to 1.98) | -2.4 (-6.12 to 1.35) |
| Change at Week 18 | -31.2 (-35.63 to -26.83) | -25.0 (-29.41 to -20.55) | -22.5 (-26.94 to -18.07) | -17.5 (-22.02 to -13.02) | -2.4 (-8.87 to 3.97) | -3.9 (-8.31 to 0.43) |
| Change at Week 24 | -36.5 (-41.54 to -31.53) | -29.2 (-34.21 to -24.15) | -33.3 (-38.33 to -28.25) | -23.6 (-28.72 to -18.45) | -4.2 (-11.50 to 3.13) | -5.1 (-10.03 to -0.13) |
SALT is a quantitative assessment of AA severity based on the scalp hair loss. The SALT score can vary from 0 (normal) to 100 (severe), with higher scores representing increased severity of disease. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Baseline | 90.3 ± 15.05 | 90.5 ± 14.28 | 90.3 ± 14.69 | 90.0 ± 15.07 | 88.3 ± 16.87 | 94.4 ± 9.31 | 91.5 ± 13.22 |
| Change at Week 28 | -44.1 ± 36.35 | -33.3 ± 33.85 | -36.1 ± 33.42 | -29.2 ± 32.56 | -5.6 ± 23.15 | -11.5 ± 22.75 | -5.0 ± 18.51 |
| Change at Week 34 | -48.2 ± 36.16 | -35.5 ± 35.50 | -43.6 ± 34.35 | -33.5 ± 35.01 | -7.6 ± 23.61 | -27.5 ± 32.78 | -12.6 ± 24.47 |
| Change at Week 40 | -49.3 ± 36.11 | -38.5 ± 37.14 | -46.9 ± 35.68 | -35.9 ± 35.90 | -11.4 ± 26.01 | -36.5 ± 34.56 | -23.0 ± 30.64 |
| Change at Week 48 | -49.4 ± 36.09 | -40.5 ± 37.27 | -48.9 ± 36.63 | -40.1 ± 35.87 | -13.3 ± 30.13 | -46.3 ± 35.51 | -32.2 ± 32.39 |
EBA is a numeric rating scale developed to characterize eyebrow hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0= no eyebrow, 1=minimal eyebrow, 2=moderate eyebrow and 3= normal eyebrow, where higher scores represent less hair loss of eyebrows.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 1.87 (0.00 to 4.44) | 2.88 (0.00 to 6.10) | 0.00 (NA to NA) | 0.93 (0.00 to 2.76) | 1.96 (0.00 to 5.77) | 0.00 (NA to NA) | 3.85 (0.00 to 9.07) |
| Week 8 | 10.28 (4.53 to 16.03) | 13.86 (7.12 to 20.60) | 2.97 (0.00 to 6.28) | 4.90 (0.71 to 9.09) | 3.85 (0.00 to 9.07) | 3.77 (0.00 to 8.90) | 0.00 (NA to NA) |
| Week 12 | 22.86 (14.83 to 30.89) | 17.48 (10.14 to 24.81) | 9.62 (3.95 to 15.28) | 7.62 (2.54 to 12.69) | 6.25 (0.00 to 13.10) | 0.00 (NA to NA) | 4.00 (0.00 to 9.43) |
| Week 18 | 29.70 (20.79 to 38.61) | 18.81 (11.19 to 26.43) | 17.82 (10.36 to 25.29) | 12.87 (6.34 to 19.40) | 10.20 (1.73 to 18.68) | 0.00 (NA to NA) | 8.16 (0.50 to 15.83) |
| Week 24 | 33.98 (24.83 to 43.13) | 25.49 (17.03 to 33.95) | 29.00 (20.11 to 37.89) | 16.67 (9.43 to 23.90) | 8.33 (0.51 to 16.15) | 3.64 (0.00 to 8.58) | 5.77 (0.00 to 12.11) |
| Week 28 | 37.00 (27.54 to 46.46) | 29.00 (20.11 to 37.89) | 27.27 (18.50 to 36.05) | 24.76 (16.51 to 33.02) | 12.24 (3.07 to 21.42) | 4.17 (0.00 to 9.82) | 6.00 (0.00 to 12.58) |
| Week 34 | 41.35 (31.88 to 50.81) | 30.77 (21.90 to 39.64) | 34.65 (25.37 to 43.93) | 31.43 (22.55 to 40.31) | 14.58 (4.60 to 24.57) | 15.69 (5.71 to 25.67) | 13.46 (4.18 to 22.74) |
| Week 40 | 43.40 (33.96 to 52.83) | 30.39 (21.47 to 39.32) | 39.00 (29.44 to 48.56) | 33.65 (24.57 to 42.74) | 16.00 (5.84 to 26.16) | 20.00 (9.43 to 30.57) | 26.92 (14.87 to 38.98) |
| Week 48 | 42.99 (33.61 to 52.37) | 32.67 (23.53 to 41.82) | 43.56 (33.89 to 53.23) | 33.33 (24.32 to 42.35) | 16.00 (5.84 to 26.16) | 30.91 (18.70 to 43.12) | 31.37 (18.64 to 44.11) |
ELA is a numeric rating scale developed to characterize eyelash hair loss. The numeric rating scale ranges from 0 (none) to 3 (normal), where, 0=no eyelash, 1=minimal eyelash, 2=moderate eyelash and 3=normal eyelash, where higher scores represent less hair loss of eyelash.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 3.03 (0.00 to 6.41) | 1.08 (0.00 to 3.17) | 5.38 (0.79 to 9.96) | 1.03 (0.00 to 3.04) | 4.55 (0.00 to 10.70) | 2.04 (0.00 to 6.00) | 0.00 (NA to NA) |
| Week 8 | 9.09 (3.43 to 14.75) | 4.44 (0.19 to 8.70) | 8.79 (2.97 to 14.61) | 4.35 (0.18 to 8.51) | 2.22 (0.00 to 6.53) | 2.04 (0.00 to 6.00) | 0.00 (NA to NA) |
| Week 12 | 16.49 (9.11 to 23.88) | 10.99 (4.56 to 17.41) | 11.70 (5.20 to 18.20) | 7.37 (2.11 to 12.62) | 4.76 (0.00 to 11.20) | 0.00 (NA to NA) | 0.00 (NA to NA) |
| Week 18 | 25.53 (16.72 to 34.35) | 20.00 (11.74 to 28.26) | 20.00 (11.74 to 28.26) | 12.09 (5.39 to 18.79) | 6.98 (0.00 to 14.59) | 2.17 (0.00 to 6.39) | 0.00 (NA to NA) |
| Week 24 | 30.21 (21.02 to 39.39) | 21.35 (12.84 to 29.86) | 28.89 (19.52 to 38.25) | 26.09 (17.11 to 35.06) | 4.88 (0.00 to 11.47) | 9.80 (1.64 to 17.97) | 0.00 (NA to NA) |
| Week 28 | 29.79 (20.54 to 39.03) | 25.00 (15.95 to 34.05) | 36.78 (26.65 to 46.91) | 24.21 (15.60 to 32.82) | 4.76 (0.00 to 11.20) | 6.82 (0.00 to 14.27) | 4.55 (0.00 to 10.70) |
| Week 34 | 34.02 (24.59 to 43.45) | 26.37 (17.32 to 35.43) | 38.89 (28.82 to 48.96) | 26.32 (17.46 to 35.17) | 7.32 (0.00 to 15.29) | 16.67 (6.12 to 27.21) | 6.52 (0.00 to 13.66) |
| Week 40 | 39.80 (30.10 to 49.49) | 28.09 (18.75 to 37.43) | 38.20 (28.11 to 48.30) | 27.66 (18.62 to 36.70) | 18.60 (6.97 to 30.24) | 25.49 (13.53 to 37.45) | 17.39 (6.44 to 28.34) |
| Week 48 | 38.38 (28.80 to 47.96) | 29.55 (20.01 to 39.08) | 40.00 (29.88 to 50.12) | 30.53 (21.27 to 39.79) | 20.93 (8.77 to 33.09) | 37.25 (23.99 to 50.52) | 35.56 (21.57 to 49.54) |
PGI-C is a self-administered questionnaire to evaluate the improvement or worsening of participant's AA as compared to the start of the study. PGI-C was assessed on a 7-point Likert scale ranged from 1 (greatly improved) to 7 (greatly worsened). Categories were defined based on the PGI-C scores as follows: 1=greatly improved, 2=moderately improved, 3=slightly improved, 4=not changed, 5=slightly worsened, 6=moderately worsened and 7=greatly worsened.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4: greatly improved | 5.43 | 4.03 | 2.36 | 0 | 0 | 0 | 0 |
| Week 4: moderately improved | 3.10 | 11.29 | 4.72 | 7.87 | 1.61 | 1.59 | 1.54 |
| Week 8: greatly improved | 17.19 | 14.88 | 8.13 | 4.13 | 1.64 | 1.59 | 1.56 |
| Week 8: moderately improved | 13.28 | 21.49 | 7.32 | 16.53 | 4.92 | 3.17 | 4.69 |
| Week 12: greatly improved | 22.83 | 22.58 | 13.60 | 12.20 | 3.39 | 0 | 3.17 |
| Week 12: moderately improved | 18.11 | 19.35 | 14.40 | 14.63 | 3.39 | 10.00 | 7.94 |
| Week 18: greatly improved | 27.64 | 22.31 | 18.03 | 19.33 | 1.64 | 1.67 | 3.28 |
| Week 18: moderately improved | 23.58 | 23.97 | 27.87 | 15.13 | 6.56 | 10.00 | 4.92 |
| Week 24: greatly improved | 36.51 | 26.45 | 28.80 | 28.93 | 1.67 | 1.54 | 4.62 |
| Week 24: moderately improved | 16.67 | 20.66 | 20.80 | 13.22 | 10.00 | 9.23 | 3.08 |
| Week 34: greatly improved | 43.20 | 35.54 | 37.40 | 31.97 | 5.08 | 18.64 | 7.81 |
| Week 34: moderately improved | 12.00 | 17.36 | 15.45 | 15.57 | 6.78 | 22.03 | 20.31 |
| Week 40: greatly improved | 43.75 | 34.68 | 37.70 | 30.00 | 6.78 | 30.77 | 13.85 |
| Week 40: moderately improved | 15.63 | 14.52 | 14.75 | 19.17 | 11.86 | 24.62 | 15.38 |
| Week 48: greatly improved | 44.96 | 33.33 | 42.40 | 31.15 | 6.56 | 42.19 | 26.56 |
| Week 48: moderately improved | 13.18 | 18.70 | 13.60 | 18.03 | 9.84 | 17.19 | 17.19 |
AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Change at Week 4: emotional symptoms | -0.37 (-0.49 to -0.25) | -0.22 (-0.34 to -0.10) | -0.33 (-0.45 to -0.21) | -0.31 (-0.44 to -0.19) | -0.29 (-0.47 to -0.11) | -0.28 (-0.40 to -0.16) |
| Change at Week 8: emotional symptoms | -0.50 (-0.62 to -0.38) | -0.46 (-0.58 to -0.34) | -0.50 (-0.62 to -0.37) | -0.36 (-0.48 to -0.23) | -0.45 (-0.62 to -0.27) | -0.39 (-0.51 to -0.27) |
| Change at Week 12: emotional symptoms | -0.53 (-0.66 to -0.40) | -0.54 (-0.67 to -0.41) | -0.48 (-0.61 to -0.34) | -0.49 (-0.63 to -0.36) | -0.50 (-0.69 to -0.31) | -0.36 (-0.49 to -0.23) |
| Change at Week 18: emotional symptoms | -0.64 (-0.78 to -0.51) | -0.57 (-0.71 to -0.44) | -0.60 (-0.74 to -0.46) | -0.54 (-0.68 to -0.40) | -0.44 (-0.63 to -0.24) | -0.43 (-0.56 to -0.29) |
| Change at Week 24: emotional symptoms | -0.61 (-0.75 to -0.46) | -0.61 (-0.76 to -0.47) | -0.69 (-0.83 to -0.54) | -0.58 (-0.72 to -0.43) | -0.49 (-0.70 to -0.28) | -0.47 (-0.61 to -0.33) |
| Change at Week 4: activity limitations | -0.19 (-0.29 to -0.08) | -0.04 (-0.15 to 0.07) | -0.16 (-0.27 to -0.05) | -0.13 (-0.24 to -0.02) | -0.20 (-0.36 to -0.04) | -0.18 (-0.29 to -0.07) |
| Change at Week 8: activity limitations | -0.24 (-0.34 to -0.13) | -0.25 (-0.36 to -0.14) | -0.18 (-0.29 to -0.07) | -0.09 (-0.20 to 0.02) | -0.21 (-0.37 to -0.05) | -0.20 (-0.31 to -0.09) |
| Change at Week 12: activity limitations | -0.27 (-0.38 to -0.17) | -0.22 (-0.32 to -0.11) | -0.21 (-0.32 to -0.11) | -0.24 (-0.35 to -0.13) | -0.27 (-0.42 to -0.11) | -0.21 (-0.32 to -0.11) |
| Change at Week 18: activity limitations | -0.35 (-0.45 to -0.24) | -0.26 (-0.36 to -0.15) | -0.23 (-0.34 to -0.12) | -0.23 (-0.34 to -0.12) | -0.28 (-0.44 to -0.13) | -0.26 (-0.36 to -0.15) |
| Change at Week 24: activity limitations | -0.30 (-0.40 to -0.20) | -0.30 (-0.40 to -0.20) | -0.31 (-0.41 to -0.21) | -0.28 (-0.38 to -0.18) | -0.31 (-0.45 to -0.16) | -0.29 (-0.39 to -0.19) |
AAPPO scale is 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over past week. Items 1-4 assessed current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss'. Items 5-8 assessed emotional symptoms. Response choices on these items were scored from 0 ='never' to 4='always'. Items 9-11 assessed activity limitations. Response choices on these items were scored from 0='not at all' to 4='completely'. Change from baseline in AAPPO emotional symptoms sub score were calculated as mean of items 5-8 and ranged from 0(never) to 4(always), where higher scores indicated more emotional symptoms. Change from baseline in AAPPO activity limitations sub score was calculated as mean of items 9-11 and ranged from 0(not at all) to 4(completely), where higher scores indicated more activity limitations. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Change at Week 34: emotional symptoms | -0.78 ± 0.95 | -0.72 ± 1.00 | -0.72 ± 0.93 | -0.71 ± 1.06 | -0.62 ± 0.83 | -0.77 ± 0.92 | -0.64 ± 0.91 |
| Change at Week 40: emotional symptoms | -0.84 ± 1.04 | -0.80 ± 1.02 | -0.81 ± 0.98 | -0.83 ± 1.11 | -0.62 ± 0.96 | -0.83 ± 1.01 | -0.66 ± 1.00 |
| Change at Week 48: emotional symptoms | -0.96 ± 0.99 | -0.84 ± 1.07 | -0.85 ± 1.04 | -0.72 ± 1.15 | -0.50 ± 0.89 | -0.98 ± 1.05 | -0.68 ± 1.03 |
| Change at Week 34: activity limitations | -0.37 ± 0.71 | -0.31 ± 0.78 | -0.26 ± 0.73 | -0.37 ± 0.78 | -0.33 ± 0.76 | -0.36 ± 0.59 | -0.42 ± 0.78 |
| Change at Week 40: activity limitations | -0.44 ± 0.76 | -0.33 ± 0.84 | -0.25 ± 0.68 | -0.42 ± 0.81 | -0.23 ± 0.71 | -0.40 ± 0.66 | -0.39 ± 0.84 |
| Change at Week 48: activity limitations | -0.43 ± 0.79 | -0.39 ± 0.84 | -0.29 ± 0.76 | -0.36 ± 0.85 | -0.26 ± 0.90 | -0.44 ± 0.71 | -0.36 ± 0.81 |
AAPPO scale is a 11-item self-administered questionnaire that measured hair loss, emotional symptoms, and activity limitations over the past week. Items 1-4 were to assess the current hair loss, eyebrow loss, eyelash loss and body hair loss and were analyzed separately on a scale of 0-4, with 0 ='no hair loss' and 4='complete hair loss', where higher scores indicated more hair loss.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4: current hair loss on scalp | 11.38 (5.77 to 16.99) | 9.76 (4.51 to 15.00) | 4.17 (0.59 to 7.74) | 4.84 (1.06 to 8.62) | 1.69 (0.00 to 4.99) | 6.35 (0.33 to 12.37) | 3.17 (0.00 to 7.50) |
| Week 8: current hair loss on scalp | 11.48 (5.82 to 17.13) | 16.67 (10.00 to 23.33) | 7.76 (2.89 to 12.63) | 8.47 (3.45 to 13.50) | 1.72 (0.00 to 5.07) | 4.76 (0.00 to 10.02) | 8.06 (1.29 to 14.84) |
| Week 12: current hair loss on scalp | 20.66 (13.45 to 27.88) | 19.51 (12.51 to 26.52) | 12.71 (6.70 to 18.72) | 13.33 (7.25 to 19.42) | 3.57 (0.00 to 8.43) | 6.67 (0.35 to 12.98) | 4.92 (0.00 to 10.34) |
| Week 18: current hair loss on scalp | 27.35 (19.27 to 35.43) | 25.00 (17.25 to 32.75) | 13.79 (7.52 to 20.07) | 16.38 (9.64 to 23.11) | 8.62 (1.40 to 15.84) | 8.33 (1.34 to 15.33) | 6.78 (0.36 to 13.19) |
| Week 24: current hair loss on scalp | 35.83 (27.25 to 44.41) | 30.00 (21.80 to 38.20) | 26.27 (18.33 to 34.21) | 24.58 (16.81 to 32.34) | 5.26 (0.00 to 11.06) | 10.77 (3.23 to 18.31) | 6.35 (0.33 to 12.37) |
| Week 34: current hair loss on scalp | 42.02 (33.15 to 50.89) | 34.45 (25.92 to 42.99) | 29.31 (21.03 to 37.59) | 30.25 (22.00 to 38.51) | 7.14 (0.40 to 13.89) | 22.03 (11.46 to 32.61) | 11.29 (3.41 to 19.17) |
| Week 40: current hair loss on scalp | 41.80 (33.05 to 50.56) | 36.59 (28.07 to 45.10) | 35.65 (26.90 to 44.41) | 32.48 (23.99 to 40.96) | 8.93 (1.46 to 16.40) | 29.23 (18.17 to 40.29) | 19.05 (9.35 to 28.74) |
| Week 48: current hair loss on scalp | 42.28 (33.55 to 51.01) | 33.61 (25.22 to 41.99) | 42.37 (33.46 to 51.29) | 32.77 (24.34 to 41.21) | 8.62 (1.40 to 15.84) | 33.85 (22.34 to 45.35) | 20.97 (10.83 to 31.10) |
| Week 4: current hair loss on eyebrows | 9.09 (3.43 to 14.75) | 7.14 (2.04 to 12.24) | 7.45 (2.14 to 12.75) | 4.17 (0.17 to 8.16) | 4.35 (0.00 to 10.24) | 6.25 (0.00 to 13.10) | 8.70 (0.55 to 16.84) |
| Week 8: current hair loss on eyebrows | 17.35 (9.85 to 24.84) | 21.05 (12.85 to 29.25) | 11.96 (5.33 to 18.59) | 10.99 (4.56 to 17.41) | 6.52 (0.00 to 13.66) | 4.17 (0.00 to 9.82) | 11.11 (1.93 to 20.29) |
| Week 12: current hair loss on eyebrows | 27.84 (18.92 to 36.75) | 27.84 (18.92 to 36.75) | 18.09 (10.30 to 25.87) | 15.96 (8.55 to 23.36) | 11.63 (2.05 to 21.21) | 11.11 (1.93 to 20.29) | 6.82 (0.00 to 14.27) |
| Week 18: current hair loss on eyebrows | 27.66 (18.62 to 36.70) | 33.68 (24.18 to 43.19) | 27.47 (18.30 to 36.64) | 19.78 (11.60 to 27.96) | 13.33 (3.40 to 23.27) | 11.11 (1.93 to 20.29) | 7.14 (0.00 to 14.93) |
| Week 24: current hair loss on eyebrows | 32.29 (22.94 to 41.65) | 32.98 (23.47 to 42.48) | 30.43 (21.03 to 39.84) | 29.35 (20.04 to 38.65) | 6.82 (0.00 to 14.27) | 12.00 (2.99 to 21.01) | 10.87 (1.87 to 19.86) |
| Week 34: current hair loss on eyebrows | 42.71 (32.81 to 52.60) | 38.71 (28.81 to 48.61) | 38.89 (28.82 to 48.96) | 31.91 (22.49 to 41.34) | 16.28 (5.24 to 27.31) | 22.73 (10.34 to 35.11) | 13.33 (3.40 to 23.27) |
| Week 40: current hair loss on eyebrows | 42.27 (32.44 to 52.10) | 36.84 (27.14 to 46.54) | 38.89 (28.82 to 48.96) | 38.04 (28.12 to 47.96) | 20.00 (8.31 to 31.69) | 32.00 (19.07 to 44.93) | 23.91 (11.59 to 36.24) |
| Week 48: current hair loss on eyebrows | 44.90 (35.05 to 54.75) | 34.04 (24.46 to 43.62) | 43.96 (33.76 to 54.15) | 39.36 (29.49 to 49.24) | 15.56 (4.97 to 26.14) | 38.00 (24.55 to 51.45) | 33.33 (19.56 to 47.11) |
| Week 4: current hair loss on eyelashes | 11.49 (4.79 to 18.20) | 4.60 (0.20 to 9.00) | 7.59 (1.75 to 13.44) | 9.30 (3.16 to 15.44) | 5.26 (0.00 to 12.36) | 8.89 (0.57 to 17.20) | 5.26 (0.00 to 12.36) |
| Week 8: current hair loss on eyelashes | 17.44 (9.42 to 25.46) | 17.65 (9.54 to 25.75) | 12.82 (5.40 to 20.24) | 14.81 (7.08 to 22.55) | 7.89 (0.00 to 16.47) | 6.67 (0.00 to 13.95) | 8.11 (0.00 to 16.90) |
| Week 12: current hair loss on eyelashes | 29.41 (19.73 to 39.10) | 26.74 (17.39 to 36.10) | 16.46 (8.28 to 24.63) | 19.05 (10.65 to 27.44) | 8.33 (0.00 to 17.36) | 14.63 (3.82 to 25.45) | 8.33 (0.00 to 17.36) |
| Week 18: current hair loss on eyelashes | 31.33 (21.35 to 41.30) | 37.65 (27.35 to 47.95) | 21.05 (11.89 to 30.22) | 22.22 (13.17 to 31.28) | 7.89 (0.00 to 16.47) | 12.20 (2.18 to 22.21) | 2.94 (0.00 to 8.62) |
| Week 24: current hair loss on eyelashes | 31.40 (21.59 to 41.20) | 42.17 (31.54 to 52.79) | 31.17 (20.82 to 41.51) | 28.05 (18.33 to 37.77) | 8.33 (0.00 to 17.36) | 13.04 (3.31 to 22.78) | 2.63 (0.00 to 7.72) |
| Week 34: current hair loss on eyelashes | 40.00 (29.59 to 50.41) | 36.59 (26.16 to 47.01) | 37.33 (26.39 to 48.28) | 34.52 (24.36 to 44.69) | 11.43 (0.89 to 21.97) | 21.43 (9.02 to 33.84) | 13.51 (2.50 to 24.53) |
| Week 40: current hair loss on eyelashes | 43.02 (32.56 to 53.49) | 39.29 (28.84 to 49.73) | 32.89 (22.33 to 43.46) | 36.59 (26.16 to 47.01) | 10.81 (0.81 to 20.82) | 28.26 (15.25 to 41.27) | 13.16 (2.41 to 23.91) |
| Week 48: current hair loss on eyelashes | 41.86 (31.43 to 52.29) | 37.35 (26.94 to 47.76) | 38.16 (27.24 to 49.08) | 34.52 (24.36 to 44.69) | 8.11 (0.00 to 16.90) | 39.13 (25.03 to 53.23) | 28.95 (14.53 to 43.37) |
| Week 4: current hair loss on body | 11.46 (5.09 to 17.83) | 9.28 (3.50 to 15.05) | 10.42 (4.31 to 16.53) | 6.38 (1.44 to 11.32) | 2.13 (0.00 to 6.25) | 4.26 (0.00 to 10.03) | 11.36 (1.99 to 20.74) |
| Week 8: current hair loss on body | 14.74 (7.61 to 21.86) | 15.96 (8.55 to 23.36) | 13.98 (6.93 to 21.03) | 10.11 (3.85 to 16.38) | 2.17 (0.00 to 6.39) | 6.38 (0.00 to 13.37) | 11.63 (2.05 to 21.21) |
| Week 12: current hair loss on body | 17.02 (9.42 to 24.62) | 19.15 (11.19 to 27.10) | 14.89 (7.70 to 22.09) | 14.29 (7.10 to 21.48) | 4.44 (0.00 to 10.47) | 11.36 (1.99 to 20.74) | 7.14 (0.00 to 14.93) |
| Week 18: current hair loss on body | 19.78 (11.60 to 27.96) | 25.00 (16.15 to 33.85) | 15.05 (7.79 to 22.32) | 15.91 (8.27 to 23.55) | 10.64 (1.82 to 19.45) | 9.09 (0.60 to 17.59) | 7.50 (0.00 to 15.66) |
| Week 24: current hair loss on body | 25.81 (16.91 to 34.70) | 27.96 (18.84 to 37.08) | 20.43 (12.24 to 28.62) | 22.22 (13.63 to 30.81) | 6.67 (0.00 to 13.95) | 16.33 (5.98 to 26.68) | 11.36 (1.99 to 20.74) |
| Week 34: current hair loss on body | 33.33 (23.75 to 42.91) | 33.70 (24.04 to 43.35) | 31.52 (22.03 to 41.02) | 26.09 (17.11 to 35.06) | 11.36 (1.99 to 20.74) | 22.73 (10.34 to 35.11) | 9.30 (0.62 to 17.98) |
| Week 40: current hair loss on body | 35.11 (25.46 to 44.76) | 36.17 (26.46 to 45.88) | 30.77 (21.29 to 40.25) | 25.56 (16.54 to 34.57) | 8.70 (0.55 to 16.84) | 22.45 (10.77 to 34.13) | 11.36 (1.99 to 20.74) |
| Week 48: current hair loss on body | 34.74 (25.16 to 44.31) | 34.41 (24.75 to 44.06) | 36.56 (26.77 to 46.35) | 30.43 (21.03 to 39.84) | 10.87 (1.87 to 19.86) | 34.69 (21.37 to 48.02) | 20.45 (8.54 to 32.37) |
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Change at Week 4 | -0.1 (-0.54 to 0.26) | -0.4 (-0.82 to -0.01) | -0.1 (-0.48 to 0.33) | -0.1 (-0.48 to 0.33) | -0.3 (-0.86 to 0.32) | -0.3 (-0.73 to 0.07) |
| Change at Week 8 | -0.5 (-0.89 to -0.06) | -0.3 (-0.71 to 0.12) | -0.2 (-0.58 to 0.26) | 0.2 (-0.25 to 0.59) | -0.2 (-0.79 to 0.43) | -0.3 (-0.73 to 0.10) |
| Change at Week 12 | -0.6 (-1.04 to -0.21) | -0.4 (-0.81 to 0.03) | 0.0 (-0.45 to 0.39) | 0.1 (-0.32 to 0.53) | -0.5 (-1.07 to 0.15) | -0.1 (-0.53 to 0.30) |
| Change at Week 24 | -0.4 (-0.79 to 0.07) | -0.8 (-1.21 to -0.35) | -0.3 (-0.70 to 0.16) | -0.2 (-0.66 to 0.21) | -0.4 (-1.04 to 0.21) | 0.0 (-0.46 to 0.39) |
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Baseline | 2.7 ± 2.60 | 3.0 ± 3.16 | 2.9 ± 3.00 | 2.8 ± 2.99 | 2.8 ± 2.80 | 3.2 ± 3.36 | 3.3 ± 3.54 |
| Change at Week 48 | -0.7 ± 2.13 | -0.4 ± 3.15 | -0.3 ± 2.67 | -0.6 ± 2.44 | -0.5 ± 2.53 | -0.9 ± 3.25 | -0.4 ± 3.28 |
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo |
|---|---|---|---|---|---|---|
| Change at Week 4 | -0.3 (-0.78 to 0.08) | -0.4 (-0.79 to 0.08) | -0.4 (-0.79 to 0.08) | -0.5 (-0.97 to -0.10) | -0.6 (-1.25 to 0.02) | -0.1 (-0.54 to 0.32) |
| Change at Week 8 | -0.8 (-1.25 to -0.31) | -0.4 (-0.88 to 0.07) | -0.8 (-1.27 to -0.31) | -0.3 (-0.79 to 0.17) | -0.9 (-1.59 to -0.20) | -0.5 (-0.96 to -0.03) |
| Change at Week 12 | -0.7 (-1.22 to -0.28) | -0.9 (-1.40 to -0.46) | -0.7 (-1.22 to -0.27) | -0.3 (-0.77 to 0.19) | -0.9 (-1.55 to -0.17) | -0.4 (-0.84 to 0.09) |
| Change at Week 24 | -0.8 (-1.26 to -0.25) | -0.7 (-1.19 to -0.18) | -0.8 (-1.28 to -0.27) | -0.3 (-0.76 to 0.26) | -1.0 (-1.69 to -0.21) | -0.6 (-1.06 to -0.07) |
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms. Baseline was defined as pre-dose on Day 1.
| Units on a scale | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Baseline | 4.6 ± 3.84 | 4.5 ± 3.18 | 4.9 ± 3.31 | 4.3 ± 3.42 | 5.2 ± 3.38 | 5.3 ± 4.20 | 5.3 ± 3.70 |
| Change at Week 48 | -1.0 ± 2.92 | -0.8 ± 3.10 | -0.8 ± 3.09 | -0.5 ± 3.40 | -1.2 ± 2.89 | -1.3 ± 3.31 | -0.5 ± 4.53 |
HADS is a validated 14-item PRO measure used to assess states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for depression subscale; higher score indicating greater severity of depression symptoms.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 42.86 (6.20 to 79.52) | 60.00 (29.64 to 90.36) | 53.85 (26.75 to 80.95) | 42.86 (16.93 to 68.78) | 40.00 (0.00 to 82.94) | 60.00 (17.06 to 100.00) | 50.00 (19.01 to 80.99) |
| Week 8 | 66.67 (28.95 to 100.00) | 45.45 (16.03 to 74.88) | 58.33 (30.44 to 86.23) | 33.33 (6.66 to 60.01) | 20.00 (0.00 to 55.06) | 50.00 (1.00 to 99.00) | 40.00 (9.64 to 70.36) |
| Week 12 | 50.00 (9.99 to 90.01) | 63.64 (35.21 to 92.06) | 66.67 (39.99 to 93.34) | 30.77 (5.68 to 55.86) | 20.00 (0.00 to 55.06) | 60.00 (17.06 to 100.00) | 62.50 (28.95 to 96.05) |
| Week 24 | 71.43 (37.96 to 100.00) | 63.64 (35.21 to 92.06) | 41.67 (13.77 to 69.56) | 42.86 (16.93 to 68.78) | 50.00 (1.00 to 99.00) | 50.00 (1.00 to 99.00) | 50.00 (19.01 to 80.99) |
| Week 48 | 50.00 (9.99 to 90.01) | 63.64 (35.21 to 92.06) | 58.33 (30.44 to 86.23) | 46.15 (19.05 to 73.25) | 80.00 (44.94 to 100.00) | 60.00 (17.06 to 100.00) | 60.00 (29.64 to 90.36) |
HADS is a validated 14-item PRO measure used to assessed states of anxiety and depression over the past week. Items were rated on a 4-point severity scale. The HADS produces 2 scales, one for anxiety (HADS-A) and one for depression (HADS-D), differentiating the two states with established normal score cut-offs. The instrument have been validated for use by adolescents aged 12 and older. Each subscale comprised of 7 items and the participant responds as to how each item applies to him/her over the past week prior to baseline visit, on 4-point response scale. Separate scores were calculated for anxiety and depression with score ranges from 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range was from 0 to 21 for anxiety subscale; higher score indicating greater severity of anxiety symptoms.
| Percentage of participants | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Week 4 | 51.72 (33.54 to 69.91) | 45.45 (24.65 to 66.26) | 34.62 (16.33 to 52.90) | 37.50 (13.78 to 61.22) | 40.00 (15.21 to 64.79) | 31.58 (10.68 to 52.48) | 30.77 (5.68 to 55.86) |
| Week 8 | 46.43 (27.96 to 64.90) | 50.00 (28.09 to 71.91) | 68.00 (49.71 to 86.29) | 41.67 (13.77 to 69.56) | 71.43 (47.76 to 95.09) | 33.33 (11.56 to 55.11) | 46.15 (19.05 to 73.25) |
| Week 12 | 50.00 (31.48 to 68.52) | 57.89 (35.69 to 80.10) | 38.46 (19.76 to 57.16) | 56.25 (31.94 to 80.56) | 42.86 (16.93 to 68.78) | 47.37 (24.92 to 69.82) | 41.67 (13.77 to 69.56) |
| Week 24 | 51.85 (33.01 to 70.70) | 65.00 (44.10 to 85.90) | 50.00 (30.78 to 69.22) | 46.67 (21.42 to 71.91) | 57.14 (31.22 to 83.07) | 44.44 (21.49 to 67.40) | 38.46 (12.02 to 64.91) |
| Week 48 | 53.85 (34.68 to 73.01) | 66.67 (44.89 to 88.44) | 60.00 (40.80 to 79.20) | 50.00 (23.81 to 76.19) | 61.54 (35.09 to 87.98) | 57.89 (35.69 to 80.10) | 58.33 (30.44 to 86.23) |
Collected over Baseline up to 5 weeks after last dose of study drug (maximum up to Week 53). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 0/131 (0%) | 4/131 (3.1%) | 84/131 (64.1%) |
| Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 0/129 (0%) | 2/129 (1.6%) | 76/129 (58.9%) |
| Ritlecitinib (PF-06651600) 50 mg | 0/130 (0%) | 2/130 (1.5%) | 81/130 (62.3%) |
| Ritlecitinib (PF-06651600) 30 mg | 0/132 (0%) | 1/132 (0.8%) | 77/132 (58.3%) |
| Ritlecitinib (PF-06651600) 10 mg | 0/62 (0%) | 2/62 (3.2%) | 32/62 (51.6%) |
| Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 0/65 (0%) | 0/65 (0%) | 39/65 (60%) |
| Placebo, Ritlecitinib (PF-06651600) 50 mg | 0/66 (0%) | 3/66 (4.5%) | 39/66 (59.1%) |
| Event | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| Suicidal behaviourPsychiatric disorders | 0/131 | 1/129 | 0/130 | 0/132 | 1/62 | 0/65 | 0/66 |
| EczemaSkin and subcutaneous tissue disorders | 0/131 | 0/129 | 0/130 | 0/132 | 1/62 | 0/65 | 0/66 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/131 | 0/129 | 0/130 | 0/132 | 0/62 | 0/65 | 1/66 |
| Conversion disorderPsychiatric disorders | 0/131 | 0/129 | 0/130 | 0/132 | 0/62 | 0/65 | 1/66 |
| Heavy menstrual bleedingReproductive system and breast disorders | 0/131 | 0/129 | 0/130 | 0/132 | 0/62 | 0/65 | 1/66 |
| AppendicitisInfections and infestations | 1/131 | 1/129 | 0/130 | 0/132 | 0/62 | 0/65 | 0/66 |
| Chemical poisoningInjury, poisoning and procedural complications | 0/131 | 1/129 | 0/130 | 0/132 | 0/62 | 0/65 | 0/66 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/131 | 0/129 | 1/130 | 0/132 | 0/62 | 0/65 | 0/66 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/131 | 0/129 | 1/130 | 0/132 | 0/62 | 0/65 | 0/66 |
| EmpyemaInfections and infestations | 1/131 | 0/129 | 0/130 | 0/132 | 0/62 | 0/65 | 0/66 |
| Event | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 17/131 | 14/129 | 16/130 | 24/132 | 12/62 | 8/65 | 8/66 |
| NasopharyngitisInfections and infestations | 19/131 | 21/129 | 18/130 | 21/132 | 7/62 | 7/65 | 4/66 |
| Upper respiratory tract infectionInfections and infestations | 18/131 | 12/129 | 11/130 | 16/132 | 2/62 | 7/65 | 6/66 |
| NauseaGastrointestinal disorders | 11/131 | 3/129 | 3/130 | 12/132 | 3/62 | 8/65 | 1/66 |
| AcneSkin and subcutaneous tissue disorders | 6/131 | 10/129 | 12/130 | 12/132 | 3/62 | 5/65 | 8/66 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/131 | 3/129 | 3/130 | 5/132 | 6/62 | 0/65 | 1/66 |
| DiarrhoeaGastrointestinal disorders | 9/131 | 4/129 | 12/130 | 8/132 | 0/62 | 4/65 | 1/66 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/131 | 5/129 | 2/130 | 4/132 | 2/62 | 2/65 | 6/66 |
| FolliculitisInfections and infestations | 11/131 | 11/129 | 8/130 | 5/132 | 4/62 | 4/65 | 4/66 |
| Urinary tract infectionInfections and infestations | 11/131 | 3/129 | 1/130 | 5/132 | 0/62 | 4/65 | 2/66 |
Full analysis set (FAS) included all participants who were randomized, regardless of whether they received study medication.
| Age, Continuous(Years) | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 34.5 ± 14.98 | 33.7 ± 13.75 | 32.4 ± 13.36 | 33.7 ± 14.83 | 34.3 ± 13.88 | 33.0 ± 14.01 | 35.0 ± 15.89 | 33.8 ± 14.33 |
| Sex: Female, Male(Participants) | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 81 | 85 | 71 | 80 | 43 | 46 | 40 | 446 |
| Male | 51 | 45 | 59 | 52 | 20 | 19 | 26 | 272 |
| Ethnicity (NIH/OMB)(Participants) | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 16 | 11 | 23 | 8 | 7 | 4 | 87 |
| Not Hispanic or Latino | 113 | 114 | 116 | 109 | 55 | 58 | 61 | 626 |
| Unknown or Not Reported | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | Ritlecitinib (PF-06651600) 50 mg | Ritlecitinib (PF-06651600) 30 mg | Ritlecitinib (PF-06651600) 10 mg | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | Placebo, Ritlecitinib (PF-06651600) 50 mg | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 3 |
| Asian | 33 | 28 | 43 | 34 | 17 | 14 | 17 | 186 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 6 | 7 | 5 | 3 | 2 | 2 | 2 | 27 |
| White | 92 | 90 | 79 | 91 | 42 | 47 | 47 | 488 |
| More than one race | 0 | 3 | 1 | 2 | 0 | 2 | 0 | 8 |
| Unknown or Not Reported | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 5 |
Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2018 to primary completion in Dec 2020, 24 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600